Document is current
Any future updates will be listed below
-
Authors
Zhao, Yanmin
Luo, Yi
Shi, Jimin
Yu, Jian
Liu, Lizhen
Lai, Xiaoyu
Fu, Huarui
Zhao, Yeqian
Yu, Yi
Ye, Yishan
Zhang, Congxiao
Li, Nainong
Jiang, Erlie
Xie, Qiong
Gu, Jundong
Han, Zhibo
Han, Zhongchao
Huang, He https://orcid.org/0000-0002-2723-1621
- License Information
-
More Information
Article History
Received: 11 April 2025
Accepted: 10 June 2025
First Online: 1 July 2025
Declarations
:
: The study protocol was in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of each participating center. All included subjects signed informed consent. (1) Title: Clinical trial of human umbilical cord mesenchymal stromal cells for the treatment of refractory acute graft-versus-host disease.The First Affiliated Hospital, Zhejiang University School of Medicine Ethics Committee. Approval number: 2021(620). Date of approval: 14 February 2022. (2) Title: Clinical trial of human umbilical cord mesenchymal stromal cells for the treatment of refractory acute graft-versus-host disease. Fujian Medical University Union Hospital Ethics Committee. Approval number:22YW029-1. Date of approval: 1 April 2022. (3) Title: Clinical trial of human umbilical cord mesenchymal stromal cells for the treatment of refractory acute graft-versus-host disease. Institute of Hematology and Blood Diseases Hospital Ethics Committee. Approval number: XY2022040-EC-1.Date of approval: 29 June 2022.
: All the authors agreed to submit and publish the final manuscript.
: The authors have declared that no conflict of interest exists.
